Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EPS watch

EPS watch

Company 3Q04 EPS est 3Q04 EPS actual Outcome Growth from 3Q03 10/22 cls Wk chg % chg Mcap chg 10/22 mcap
Affymetrix (AFFX) $0.19 $0.25 Beat by $0.06 150% $29.39 -$0.22 -1% -$13 $1,780
3Q04 product and product-related revenues increased 7% to $76.2M from $71.1M in 3Q03. AFFX raised its FY04 diluted EPS guidance to $0.70 from $0.60. It continues to expect FY04 product and product-related revenues of $330-$335M.
Amgen (AMGN) $0.62 $0.64 Beat by $0.02 21% $ 52.70 -$2.52 -5% -$3,205 $66,930
Product sales

Read the full 951 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE